Recently, the gut microbiota (GM) has been recognized as an integral part of the pathogenesis of Parkinson's disease (PD). Research found a bidirectional interaction between GM and the central nervous system (CNS), known as the "microbiome-entero-brain axis". The dysregulation of GM may contribute to the occurrence or development of PD through a variety of mechanisms. In this study, we address the potential pathways of GM disorder in PD, including peripheral α-synuclein accumulation, microglial overactivation, and disruption of dopamine (DA) metabolism. Additionally, information about fecal microbiota transplantation (FMT) and oral probiotics as therapy options for PD was provided. The identification of the role gut microflora plays in PD has sparked interest in investigating novel therapy approaches and using microbes to treat the condition.

Haoan Tang, Hongjun Liu, Shaojia Chen, Xu Chen. Research and treatment discussions regarding the potential impact of gut microbiota on Parkinson's disease. International Journal of Frontiers in Medicine (2023), Vol. 5, Issue 12: 104-108. https://doi.org/10.25236/IJFM.2023.051216.

[1] Rietdijk, C.D., et al., Exploring Braak's Hypothesis of Parkinson's Disease. Front Neurol, 2017. 8: p. 37.

[2] Samii, A., J.G. Nutt, and B.R. Ransom, Parkinson's disease. Lancet, 2004. 363(9423): p. 1783-1793.

[3] Tremlett, H., et al., The gut microbiome in human neurological disease: A review. Ann Neurol, 2017. 81(3): p. 369-382.

[4] Nicholson, J.K., et al., Host-gut microbiota metabolic interactions. Science, 2012. 336(6086): p. 1262-1267.

[5] Lyte, M., Microbial endocrinology: Host-microbiota neuroendocrine interactions influencing brain and behavior. Gut Microbes, 2014. 5(3): p. 381-389.

[6] Mukherjee, A., A. Biswas, and S.K. Das, Gut dysfunction in Parkinson's disease. World J Gastroenterol, 2016. 22(25): p. 5742-5752.

[7] Sampson, T.R. and S.K. Mazmanian, Control of brain development, function, and behavior by the microbiome. Cell Host Microbe, 2015. 17(5): p. 565-576.

[8] Zheng, S.Y., et al., Potential roles of gut microbiota and microbial metabolites in Parkinson's disease. Ageing Res Rev, 2021. 69: p. 101347.

[9] Cloud, L.J. and J.G. Greene, Gastrointestinal features of Parkinson's disease. Curr Neurol Neurosci Rep, 2011. 11(4): p. 379-384.

[10] Kim, J.S. and H.Y. Sung, Gastrointestinal Autonomic Dysfunction in Patients with Parkinson's Disease. J Mov Disord, 2015. 8(2): p. 76-82.

[11] Duncan, S.H., et al., Acetate utilization and butyryl coenzyme A (CoA):acetate-CoA transferase in butyrate-producing bacteria from the human large intestine. Appl Environ Microbiol, 2002. 68(10): p. 5186-5190.

[12] Boertien, J.M., et al., Increasing Comparability and Utility of Gut Microbiome Studies in Parkinson's Disease: A Systematic Review. J Parkinsons Dis, 2019. 9(s2): p. S297-s312.

[13] Romano, S., et al., Meta-analysis of the Parkinson's disease gut microbiome suggests alterations linked to intestinal inflammation. NPJ Parkinsons Dis, 2021. 7(1): p. 27.

[14] Paiva, I., et al., Sodium butyrate rescues dopaminergic cells from alpha-synuclein-induced transcriptional deregulation and DNA damage. Hum Mol Genet, 2017. 26(12): p. 2231-2246.

[15] Sharma, S., R. Taliyan, and S. Singh, Beneficial effects of sodium butyrate in 6-OHDA induced neurotoxicity and behavioral abnormalities: Modulation of histone deacetylase activity. Behav Brain Res, 2015. 291: p. 306-314.

[16] Guo, T.T., et al., Neuroprotective Effects of Sodium Butyrate by Restoring Gut Microbiota and Inhibiting TLR4 Signaling in Mice with MPTP-Induced Parkinson's Disease. Nutrients, 2023. 15(4).

[17] Erny, D., et al., Host microbiota constantly control maturation and function of microglia in the CNS. Nat Neurosci, 2015. 18(7): p. 965-977.

[18] Claudino Dos Santos, J.C., et al., Role of enteric glia and microbiota-gut-brain axis in parkinson disease pathogenesis. Ageing Res Rev, 2023. 84: p. 101812.

[19] Persidsky, Y., et al., Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J Neuroimmune Pharmacol, 2006. 1(3): p. 223-236.

[20] Zlokovic, B.V., The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron, 2008. 57(2): p. 178-201.

[21] Baizabal-Carvallo, J.F. and M. Alonso-Juarez, The Link between Gut Dysbiosis and Neuroinflammation in Parkinson's Disease. Neuroscience, 2020. 432: p. 160-173.

[22] Pellegrini, C., et al., Microbiota-gut-brain axis in health and disease: Is NLRP3 inflammasome at the crossroads of microbiota-gut-brain communications? Prog Neurobiol, 2020. 191: p. 101806.

[23] Beitz, J.M., Parkinson's disease: a review. Front Biosci (Schol Ed), 2014. 6(1): p. 65-74.

[24] Eisenhofer, G., et al., Substantial production of dopamine in the human gastrointestinal tract. J Clin Endocrinol Metab, 1997. 82(11): p. 3864-3871.

[25] Wall, R., et al., Bacterial neuroactive compounds produced by psychobiotics. Adv Exp Med Biol, 2014. 817: p. 221-239.

[26] Andrews, Z.B., et al., Ghrelin promotes and protects nigrostriatal dopamine function via a UCP2-dependent mitochondrial mechanism. J Neurosci, 2009. 29(45): p. 14057-14065.

[27] Braak, H., et al., Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett, 2006. 396(1): p. 67-72.

[28] Shannon, K.M., et al., Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases. Mov Disord, 2012. 27(6): p. 716-719.

[29] Forsyth, C.B., et al., Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLoS One, 2011. 6(12): p. e28032.

[30] Devos, D., et al., Colonic inflammation in Parkinson's disease. Neurobiol Dis, 2013. 50: p. 42-48.

[31] Lebouvier, T., et al., Colonic biopsies to assess the neuropathology of Parkinson's disease and its relationship with symptoms. PLoS One, 2010. 5(9): p. e12728.

[32] Cryan, J.F. and T.G. Dinan, Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci, 2012. 13(10): p. 701-712.

[33] Forsythe, P. and W.A. Kunze, Voices from within: gut microbes and the CNS. Cell Mol Life Sci, 2013. 70(1): p. 55-69.

[34] Kunze, W.A., et al., Lactobacillus reuteri enhances excitability of colonic AH neurons by inhibiting calcium-dependent potassium channel opening. J Cell Mol Med, 2009. 13(8b): p. 2261-2270.

[35] Paillusson, S., et al., Activity-dependent secretion of alpha-synuclein by enteric neurons. J Neurochem, 2013. 125(4): p. 512-517.

[36] Bloch, A., et al., Alpha-synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects. Neuropathol Appl Neurobiol, 2006. 32(3): p. 284-295.

[37] Braak, H., et al., Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging, 2003. 24(2): p. 197-211.

[38] Ulusoy, A., et al., Caudo-rostral brain spreading of α-synuclein through vagal connections. EMBO Mol Med, 2013. 5(7): p. 1119-1127.

[39] Perez-Burgos, A., et al., Psychoactive bacteria Lactobacillus rhamnosus (JB-1) elicits rapid frequency facilitation in vagal afferents. Am J Physiol Gastrointest Liver Physiol, 2013. 304(2): p. G211-220.

[40] Bravo, J.A., et al., Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci U S A, 2011. 108(38): p. 16050-16055.

[41] Fang, X., Microbial treatment: the potential application for Parkinson's disease. Neurol Sci, 2019. 40(1): p. 51-58.

[42] Mertsalmi, T.H., et al., More than constipation - bowel symptoms in Parkinson's disease and their connection to gut microbiota. Eur J Neurol, 2017. 24(11): p. 1375-1383.

[43] Pierantozzi, M., et al., Reduced L-dopa absorption and increased clinical fluctuations in Helicobacter pylori-infected Parkinson's disease patients. Neurol Sci, 2001. 22(1): p. 89-91.

[44] Chenoll, E., et al., Novel probiotic Bifidobacterium bifidum CECT 7366 strain active against the pathogenic bacterium Helicobacter pylori. Appl Environ Microbiol, 2011. 77(4): p. 1335-1343.

[45] Ojetti, V., et al., Impact of Lactobacillus reuteri Supplementation on Anti-Helicobacter pylori Levofloxacin-Based Second-Line Therapy. Gastroenterol Res Pract, 2012. 2012: p. 740381.

[46] Sun, M.F., et al., Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson's disease mice: Gut microbiota, glial reaction and TLR4/TNF-α signaling pathway. Brain Behav Immun, 2018. 70: p. 48-60.

[47] Zhao, Z., et al., Fecal microbiota transplantation protects rotenone-induced Parkinson's disease mice via suppressing inflammation mediated by the lipopolysaccharide-TLR4 signaling pathway through the microbiota-gut-brain axis. Microbiome, 2021. 9(1): p. 226.